A non-randomized, open-label study to assess the impact of rounds of mass drug administration with artemisinin-piperaquine plus primaquine on malaria in São Tomé Island.

IF 3 2区医学 Q1 PARASITOLOGY

Parasites & Vectors Pub Date : 2025-05-16 DOI:10.1186/s13071-025-06768-1

Mingqiang Li, Ruixiang Tan, Peiting Chen, Herodes Sacramento Rampao, Carlos Alberto Bandeira D'almeida, Guoming Li, Jingwen Liu, Guozhuang Shi, Fei Chen, Lei Shu, Xinan Huang, Changsheng Deng, Wenfeng Guo, Jianping Song

{"title":"A non-randomized, open-label study to assess the impact of rounds of mass drug administration with artemisinin-piperaquine plus primaquine on malaria in São Tomé Island.","authors":"Mingqiang Li, Ruixiang Tan, Peiting Chen, Herodes Sacramento Rampao, Carlos Alberto Bandeira D'almeida, Guoming Li, Jingwen Liu, Guozhuang Shi, Fei Chen, Lei Shu, Xinan Huang, Changsheng Deng, Wenfeng Guo, Jianping Song","doi":"10.1186/s13071-025-06768-1","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to explore the effect of mass drug administration (MDA) on malaria transmission in low-endemic malaria areas.Methods: Mass drug administration of artemisinin-piperaquine (AP) + primaquine (PMQ) was targeted to 17,438 individuals in the Agua Grande region of São Tomé and Príncipe (STP). The participants were allocated to either a three-round MDA (3-MDA) group or to a two-round MDA (2-MDA) group. The coverage rate, compliance, adverse events and other indicators were evaluated.Results: Mass drug administration coverage rate in the 3-MDA group (20,548 person-times) was 84.23-89.14%, with a compliance of 68.38%. MDA coverage rate in the 2-MDA group (15,365 person-times) was 87.30-93.23%, with a compliance of 80.70%. The rates of MDA-related adverse reactions were low in both the 3-MDA (0.75%) and 2-MDA (0.72%) groups, and no serious adverse reactions were observed. Malaria incidence decreased by 80.47% (z = - 2.35, P = 0.019) and 72.27% (z = - 0.89, P = 0.372) in the 3-MDA and 2-MDA groups, respectively, within 1 year.Conclusions: Two or three rounds of MDA with AP and PMQ in STP safely and rapidly reduced the prevalence of malaria cases and infections. It is possible that two rounds of MDA in certain districts may achieve the desired outcomes.","PeriodicalId":19793,"journal":{"name":"Parasites & Vectors","volume":"18 1","pages":"177"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084925/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Parasites & Vectors","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13071-025-06768-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PARASITOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aim of this study was to explore the effect of mass drug administration (MDA) on malaria transmission in low-endemic malaria areas.

Methods: Mass drug administration of artemisinin-piperaquine (AP) + primaquine (PMQ) was targeted to 17,438 individuals in the Agua Grande region of São Tomé and Príncipe (STP). The participants were allocated to either a three-round MDA (3-MDA) group or to a two-round MDA (2-MDA) group. The coverage rate, compliance, adverse events and other indicators were evaluated.

Results: Mass drug administration coverage rate in the 3-MDA group (20,548 person-times) was 84.23-89.14%, with a compliance of 68.38%. MDA coverage rate in the 2-MDA group (15,365 person-times) was 87.30-93.23%, with a compliance of 80.70%. The rates of MDA-related adverse reactions were low in both the 3-MDA (0.75%) and 2-MDA (0.72%) groups, and no serious adverse reactions were observed. Malaria incidence decreased by 80.47% (z = - 2.35, P = 0.019) and 72.27% (z = - 0.89, P = 0.372) in the 3-MDA and 2-MDA groups, respectively, within 1 year.

Conclusions: Two or three rounds of MDA with AP and PMQ in STP safely and rapidly reduced the prevalence of malaria cases and infections. It is possible that two rounds of MDA in certain districts may achieve the desired outcomes.

查看原文本刊更多论文

一项非随机、开放标签的研究，旨在评估在 o tom岛以青蒿素-哌喹加伯氨喹进行的轮次大规模给药对疟疾的影响。

背景：本研究旨在探讨大规模给药（MDA）对疟疾低流行地区疟疾传播的影响。方法：对 o tom和Príncipe (STP) Agua Grande地区的17,438例患者进行青蒿素-哌喹(AP) +伯氨喹（PMQ）的大规模给药。参与者被分配到三轮MDA （3-MDA）组或两轮MDA （2-MDA）组。评估覆盖率、依从性、不良事件等指标。结果：3-MDA组人群给药覆盖率为84.23 ~ 89.14%（20548人次），依从性为68.38%。2-MDA组（15365人次）的MDA覆盖率为87.30-93.23%，依从性为80.70%。3-MDA组和2-MDA组的不良反应发生率均较低（0.75%），未见严重不良反应发生。1年内，3-MDA组和2-MDA组疟疾发病率分别下降80.47% （z = - 2.35, P = 0.019）和72.27% （z = - 0.89, P = 0.372）。结论：在STP中，两到三轮MDA联合AP和PMQ安全、快速地降低了疟疾病例和感染的流行。在某些地区，两轮的MDA可能会达到预期的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Parasites & Vectors 医学-寄生虫学

CiteScore

6.30

自引率

9.40%

发文量

433

审稿时长

1.4 months

期刊介绍： Parasites & Vectors is an open access, peer-reviewed online journal dealing with the biology of parasites, parasitic diseases, intermediate hosts, vectors and vector-borne pathogens. Manuscripts published in this journal will be available to all worldwide, with no barriers to access, immediately following acceptance. However, authors retain the copyright of their material and may use it, or distribute it, as they wish. Manuscripts on all aspects of the basic and applied biology of parasites, intermediate hosts, vectors and vector-borne pathogens will be considered. In addition to the traditional and well-established areas of science in these fields, we also aim to provide a vehicle for publication of the rapidly developing resources and technology in parasite, intermediate host and vector genomics and their impacts on biological research. We are able to publish large datasets and extensive results, frequently associated with genomic and post-genomic technologies, which are not readily accommodated in traditional journals. Manuscripts addressing broader issues, for example economics, social sciences and global climate change in relation to parasites, vectors and disease control, are also welcomed.